Please select the option that best describes you:
Topics:
Gynecologic Cancers • Ovarian Cancer
When do you discontinue PARP inhibitor maintenance after complete response to first line chemotherapy in a BRCA+ patient?
Is there a role for continuing beyond 24 months?
Answer from: Medical Oncologist at Community Practice
I agree with Dr. @Rebecca C. Arend that we have no data for PARPi maintenance beyond 2 years in the first line and would urge people to enroll in clinical trials which look at risks and benefits of longer maintenance, especially in patients harbouring a germline BRCA mutation.
With respect to ...
Sign in or Register to read more
Answer from: at Academic Institution
Though it hasn't happened to me yet, the data would suggest no indication to continue PARPi beyond 2 years.